Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InMed Pharmaceuticals ( (INM) ) has shared an announcement.
InMed Pharmaceuticals has received formal notice from Nasdaq that its shares have traded below the US$1.00 minimum bid price for 30 consecutive sessions, putting the company out of compliance with Nasdaq Capital Market listing rules. The stock will continue to trade under the ticker INM while the company monitors its share price and evaluates options to restore compliance.
Under Nasdaq procedures, InMed has 180 days to lift its closing bid to at least US$1.00 for 10 straight trading days, with the possibility of a further 180-day extension if it meets other listing standards. Failure to regain compliance could ultimately lead to delisting, though the company would have the right to appeal any such decision to a Nasdaq hearings panel, creating a period of uncertainty for investors.
The most recent analyst rating on (INM) stock is a Hold with a $0.66 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Neutral.
The score is primarily held down by weak financial performance (large losses, ongoing cash burn, and data consistency concerns) and a technically bearish trend (below major moving averages with negative MACD). Limited valuation support (no dividend and P/E shown as 0.00) and earnings updates that flag liquidity and regulatory pressures further constrain the rating despite some positive pipeline progress.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a Vancouver-based pharmaceutical company developing proprietary small-molecule drug candidates that target the CB1 and CB2 receptors. Its clinical pipeline spans programs in Alzheimer’s disease, ocular disorders and dermatological indications, positioning it within the emerging field of cannabinoid-related therapeutics.
Average Trading Volume: 125,127
Technical Sentiment Signal: Sell
Current Market Cap: $1.99M
See more data about INM stock on TipRanks’ Stock Analysis page.